Logo

Adagene Inc.

ADAG

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-hu… read more

Healthcare

Biotechnology

2 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$2.00

Price

+0.25%

$0.01

Market Cap

$75.222m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$103.200k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$55.440m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.55

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$37.912m

$66.518m

Assets

$28.605m

Liabilities

$6.850m

Debt
Debt to Assets

10.3%

-0.1x

Debt to EBITDA
Free Cash Flow

-$47.587m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases